Substantial progress has been made utilizing immunotherapy in cervical cancer—specifically using checkpoint inhibition to impede immune inhibitory pathways such as programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1). Here, PDCD1 is linked to cervical cancer.